Aquaretic effects of mozavaptan hydrochloride (OPC-31260) in conscious rats and dogs

Japanese Pharmacology and Therapeutics

Volumn 34, Issue 7, 2006, Pages 835-845

  Nakamura, Shigeki ^a   Fujiki, Hiroyuki ^a   Tochizawa, Shiro ^a   Onogawa, Toshiyuki ^a   Miyazaki, Toshiki ^a   Yamamura, Yoshitaka ^a   Mori, Toyoki ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aquaretic action; Mozavaptan hydrochloride; Vasopressin V 2 receptor antagonist

Indexed keywords

FUROSEMIDE; HYDROCHLOROTHIAZIDE; MOZAVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIURESIS; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DIABETES INSIPIDUS; DOG; DOSE RESPONSE; DRUG EFFECT; FEMALE; NONHUMAN; RAT; SODIUM URINE LEVEL; URINE OSMOLALITY; URINE VOLUME;

EID: 33749462854     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Schlier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979; 236: F321-32.
2. Dubb J, Allison N, Tatoian D, Blumberg A, Lee K, Stote R. SK & F 101926 is antidiuretic in man. Kidney Int 1987; 31 (abstract): 267.
3. Brooks DP, Koster PF, Albrightson-Winslow CR, Stassen FL, Huffman WF, Kinter LB. SK & F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta). J Pharmacol Exp Ther 1988; 245: 211-5.
4. 1 antagonists: a novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2 (1H)-quinolinone. J Med Chem 1993; 36: 2011-7.
5. 2 receptor antagonist. Br J Pharmacol 1992; 105: 787-91.
6. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11: 406-10.
7. Morel F. Sites of hormone action in the mammalian nephron. Am J Physiol 1981; 240: F159-64.
8. Chabardes D, Gagnan-Brunette M, Imbert-Teboul M, Gontcharevskaia O, Montegut M, Clique A, et al. Adenylate cyclase responsiveness to hormones in various portions of the human nephron. J Clin Invest 1980; 65: 439-48.
9. Ruggles BT, Maruyama N, Werness JL, Gapstur SM, Bentley MD, Dousa TP. The vasopressin-sensitive adenylate cyclase in collecting tubules and in thick ascending limb of Henle's loop of human and canine kidney. J Clin Endocrinol Metab 1985; 60: 914-21.
10. 2 antagonist in men. J Pharmacol Exp Ther 1995; 272: 546-51.
11. 2 receptor antagonist after acute and long-term treatment in rats. Eur J Pharmacol 2000; 394: 131-8.
12. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-7.
13. Fujisawa G, Ishikawa S, Tsuboi Y, Okada K, Saito T. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int 1993; 44: 19-23.
14. Fleeman LM, Irwin PJ, Phillips PA, West J. Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone. Aust Vet J 2000; 78: 825-30.
15. Saito T, Ishikawa S, Abe K, Kamoi K, Yamada K, Shimizu K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997; 82: 1054-7.
16. Mah SC, Opperman JR, Baum HP, HofBauer KG. Biologic response to chronic blockade of vasopressin receptors in Sprague-Dawley rats. J Pharmacol Exp Ther 1988; 245: 1021-7.